Dublin, Dec. 09, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/vq...ption_pain ) has announced the addition of the "Prescription Pain Drugs - Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts" report to their offering.
Pain is defined as an unpleasant sensory and emotional experience associated with actual or potential tissue damage. At some point, everyone experiences pain. Pain may be described according to severity (mild, moderate, severe), duration (acute or chronic) or type (nociceptive, inflammatory, neuropathic). Mild-to-moderate pain, such as orthopedic and soft tissue-related pain, generally is treated with NSAIDs, celecoxib (Pfizer's Celebrex), or mild opioid analgesics, such as tramadol. Moderate-to-moderately severe pain, such as post-operative pain, orthopedic pain, and chronic back pain, generally is treated with opioid analgesics, including short-acting opioids such as hydrocodone, oxycodone, oxymorphone, and morphine, as well as extended-release formulations of oxycodone, oxymorphone, and morphine. Severe pain, including post-operative and cancer pain, generally is treated with fentanyl products, such as Duragesic, Actiq, and Fentora, as well as morphine formulations, such as Avinza and Kadian. This report deals with prescription drugs used to treat pain. While the Prescription Pain Drug market is relatively small and very mature, there are many new products coming online that have significant sales potential including Pfizer's Remoxy, Oxycodone NT and Embeda drugs, AcelRx's Zlaviso, Eagalet Corp's Oxayado, Endo/BDSI's Buprenorphine, GW Pharmaceuticals' Sativex, Insys' Subsys and dronabinol OS, Marinus' ganaxolone, as well as Bedrocan's and Tweed's medical marijuana offerings, among others. Ultimately however, Prescription Pain Drugs are very important because without them life would be intolerable for millions of people. Key Topics Covered: 1. Executive Summary 2. Introduction - Report Objectives - Methodology and Sources - Statistical Notes 3. Pain Pharmacology and Analgesia - Pain Overview - Pain According to Duration - Acute Pain - Chronic Pain - Pain According to Type - Nociceptive Pain - Inflammatory Pain - Neuropathic Pain - Emotional Response to Pain - Pain Signaling System - Pain Detection - Functional Characteristics of Pain Signaling Apparatus - Nociceptors - Primary Sensory Neurons - Primary Sensory Neurons and the Spinal Cord - Spinal Cord Neurons - Projection Neurons and the Spinal Cord - Spinal Interneurons - Pain Characteristics - Animal Models of Nociception/Pain - Neurochemical Characteristics of the Nociceptive Signaling System - Transmission of Nociceptive Information From the Periphery to the Spinal Cord - Nociceptive Neurotransmitters and Their Target Receptors - Excitatory Amino Acids and Their Receptors - Glutamate Receptors - NMDA Receptors - AMPA Receptors - Kainate Receptors - Metabotropic Glutamate Receptors (mGluRs) - Excitatory Amino Acid Transporters (EEATs) - Glycine Transporters (GlyTs) - Co-Containment of Neurotransmitters in Nerve Terminals - Descending Modulation of Nociception - Pharmacological Treatment of Pain: Analgesics and Adjuvants - Major Aims of the Treatment of Clinical Pain - Pharmacological Management of Pain - Current Treatment Guidelines - Controlled or Sustained Release Oral Formulations - Analgesic Agents - Non-Opioid Analgesics - Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Opioid Analgesics - Commonly Prescribed Opioid Analgesics - Strong Opioid Analgesics - Morphine - Oxycodone - Methadone - Hydromorphone - Fentanyl - Weak Opioid Analgesics - Codeine - Pethidine (Meperidine) - Tramadol - Partial Opioid Agonists/Antagonists: Buprenorphine - Opioid-Related Adverse Effects - Adjuvant Analgesics - Tricyclic Antidepressants - Anticonvulsants - Anti-Arrhythmics - Topical Agents - Lignocaine (Lidocaine) - Capsaicin - NMDA Receptor Antagonists - Ketamine - Dextromethorphan - Alpha(2)-Adrenergic Receptor Agonists - Invasive Procedures - Neurolytic Celiac Plexus Blockade - Implantable Intrathecal Drug Delivery - Spinal Cord Stimulation - Spinal Cord Stimulation - Future Trends 4. Prescription Pain Drugs Market - Types of Pain - Markets Segmented By Pain Severity - Market By Product Class - Market Outlook to 2020 - Opioids Market By Application - Cancer Pain Is the Largest Segment - Market Shares - Market Drivers - R&D Pipeline 5. Opioid Pain Drugs Market - Instant Vs. Extended Release Markets - Extended Release Opioids Market By Brand, Class and Producer - Opioid Prescriptions - Focus Now On Tamper Resistant/Less Addictive Opioids - DEA Allows 90-Day Rx's - DEA Reschedules Hydrocodone Combination Products - OxyContin Tamper Resistant Extends Franchise - Advances in Opioid Receptor Research - Testosterone Issues and Chronic Opioid Use - FDA Tamper Resistance Guidance - Opioids From Yeast 6. Anticonvulsant Pain Drugs Market - Neuropathic Pain Is Poorly Understood - Neuropathic Pain Drug Market - Gabapentin Now A Generic Market - Lyrica Forecast to Fall - Lyrica Sales - Cymbalta Sales - Generic Cymbalta Producers - Targeted Secretion Inhibitors For Peripheral Neuropathic Pain - Allergan's AGN-214868 Market Potential - Nerve Growth Inhibitors Put On Hold 7. Injectable/Inhaled Pain Drugs Market - Prialt Is A Niche Product - Bridion Launched in Europe - Bridion Sales to 2020 - Paion's M6G - Post-Operative Pain Market Underserved - Ofirmev Has Significant Market Potential - Ofirmev Peak Revenues - Ofirmev Satisfies A Key Need - Surgery Pain Is Poorly Addressed - Opiates Complications Are Frequent and Costly - Intravenous IV NSAIDs Have Limitations - Ofirmev Reduces Pain and Fever - EU Experience Backs Ofirmev's Potential in the U.S. - Ofirmev U.S. Sales Outlook - Ofirmev Patented Through 2021 - License With Terumo - Tanezumab Moving Forward - Tanezumab Sales Outlook 8. Topical/Transdermal Pain Drugs Market - Lidoderm Dominates the Market - Recall and Generics Hurt Duragesic - Flector Patch Has Plateaued - Flector Patch Sales - Ionsys Back in Development - Voltaren Continues to Perform Well - Voltaren Gel Sales - Zingo - NeurogesX's Qutenza - AmiKet Cream - Durect's Sufentanil Patch 9. Medical Marijuana - Dronabinol, Nabilone, Nabiximols - Marijuana - Legal Situation - Health issues - Cannabinoid Receptors and Cannabinoids - THC - CBD - Potency Trends - Research Obtained Through National Institute of Drug Abuse - Delta-9-tetrahydrocannabinol - Cannabidiol - Pharmaceutical Forms of Cannabinoids - Marijuana and Cannabinoids Potential in Cancer Pain - Marijuana Pharmaceuticals For Pain - Nabiximols - Dronabinol - Nabilone - Potential Harms of Marijuana - Cancer - Lung Problems - Neuropsychiatric - Other Problems - Outlook - Global Cannabis Market - Most Widely Cultivated Drug Plant - Global Cannabis Production - Marijuana Market vs. OTC Analgesic Market - Marinol - Medical Marijuana Market: Cannabis Vs. Dronabinol - Number of Medical Marijuana Patients Companies Mentioned - AcelRx Pharmaceuticals Inc. - Acura Pharmaceuticals, Inc. - Allergan plc - Antibe Therapeutics Inc - Bedrocan Cannabis Corp. - BioDelivery Sciences International, Inc - Cara Therapeutics, Inc. - Collegium Pharmaceutical, Inc. - Covidien plc - Durect Corporation - Egalet Corp - Elite Pharmaceuticals, Inc. - Endo International plc - GW Pharmaceuticals plc - Grünenthal GmbH - Indivior plc - Insys Therapeutics Inc - Intellipharmaceutics International Inc. - Johnson & Johnson - King Pharmaceuticals - Lannett Company, Inc. - Marinus Pharmaceuticals Inc - Mayne Pharma Group Ltd - Nektar Therapeutics - NicOx SA - Pacira Pharmaceuticals Inc - Pfizer Inc. - Purdue Pharma, L.P. - Raptor Pharmaceutical Corp. - Teva Pharmaceutical Industries Limited - Trevena Inc. - Tweed Marijuana Inc. - Zogenix, Inc For more information visit http://www.researchandmarkets.com/research/vq...ption_pain
About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Transdermal and Transmucosal Drug Delivery, Infusions and Injectables
